Axogen (AXGN) Net Equity Issued and Repurchased (2013 - 2026)

Axogen's (AXGN) quarterly Net Equity Issued and Repurchased came in at $134.0 million in Q1 2026, up 13404300.0% quarter-over-quarter from $1000.0 in Q4 2018.

Axogen (AXGN) Net Equity Issued and Repurchased (2013 - 2026) Analysis & Trends

Axogen's Net Equity Issued and Repurchased history runs 4 years deep, the most recent figure standing at $134.0 million for Q1 2026.

  • On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $134.0 million in Q1 2026; TTM through Mar 2026 was $134.0 million, a 9936719.72% increase from a year earlier, with the FY2020 full-year figure at $3.5 million, changed N/A from the prior year.
  • Net Equity Issued and Repurchased grew to $134.0 million in Q1 2026 per AXGN's latest filing, from $1000.0 in the prior quarter.
  • Across five years, Net Equity Issued and Repurchased topped out at $134.0 million in Q1 2026 and bottomed at $134.0 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn -
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn -
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn 97.00 Mn
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn -
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn -
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn 12.70 Mn
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn -
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn -
9 Smith & Nephew 25.80 Bn 25.22 Bn - -
10 Axogen 2.05 Bn 1.95 Bn 46.19 Mn 134.04 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 134.04 Mn
Mar 31, 2026 134.04 Mn
Dec 31, 2018 1,000.00
Dec 31, 2018 1,000.00
Dec 31, 2015 -2,349.00
Dec 31, 2015 -2,349.00
Sep 30, 2015 17.20 Mn
Sep 30, 2015 17.20 Mn
Jun 30, 2015 -1,399.00
Jun 30, 2015 -1,399.00
Mar 31, 2015 13.77 Mn
Mar 31, 2015 13.77 Mn
Dec 31, 2013 -6,457.00
Dec 31, 2013 -6,457.00